

**TABLE OF CONTENTS**

Preface to the 7 <sup>th</sup> Edition	i
Preface to the 6 <sup>th</sup> Edition	iii
Style Notes	vii
Acknowledgements	viii
Index of Tables	xv
Index of Figures	xviii
Definitions	xx
Some Thoughts	xxiii
<b>PART 1: GENERAL DISCUSSION</b>	<b>1</b>
Overview of the argument, and some issues	2
1 QUESTION 1: Should we attempt to prevent infectious diseases?	6
1.1 The characteristics of common infectious diseases	6
1.2 The hygiene hypothesis in orthodox and complementary medicine	13
1.2.1 Some implications of the hygiene hypothesis	14
1.3 Options	16
2 QUESTION 2: What is the best approach to infectious disease prevention - general and/or specific?	18
2.1 General methods to prevent specific diseases	18
2.1.1 Nutrition and the immune system	19
2.1.2 Nutritional deficiencies associated with immune deficiency	20
2.1.3 Sources of nutrients for the immune system	21
2.1.4 Other factors that can affect immune response	23
2.1.5 Conclusions for general immunity	24
2.2 Specific methods to prevent infectious diseases	25
2.3 General vs. Specific methods to prevent specific diseases	26
<b>PART 2: SPECIFIC METHODS OF DISEASE PREVENTION</b>	<b>27</b>
3 QUESTIONS: What are the risks and benefits of the vaccination option?	28
3.1 Basic arguments for routine vaccination	29
3.2 Problems associated with routine vaccination - summary	32

Vaccination & Homoeoprophylaxis? A Review of Risks and Alternatives - 7<sup>th</sup> Ed

3.3	The historical use of vaccination	37
3.4	The general effectiveness of vaccines	41
3.4.1	Actual disease trends - a diagrammatic summary	42
3.4.2	Clinical trials and other measures of vaccine effectiveness	54
3.5	General safety of vaccines	57
3.5.1	Routine vaccination - a summary of risks	57
3.5.2	The general risks of routine vaccination	57
3.5.3	Vaccination and Sudden Infant Death Syndrome (SIDs)	68
3.5.4	Why vaccines cause damage	68
3.5.5	The link between vaccination and chronic diseases	72
3.5.6	New research into vaccine damaged children	74
3.5.7	Conclusions to Section 3.5	79
3.5.8	Appendix 1 to Section 3.5: Vaccination and Breathing Apnoea	81
3.5.9	Appendix 2 to Section 3.5: Pre-vaccination checklist	84
3.5.10	Appendix 3 to Section 3.5: Reporting of adverse events following vaccination	86
3.5.11	Appendix 4 to Section 3.5: Thiomersal and autism	90
3.6	Specific vaccines examined	92
3.7	Some last minute findings	94
	<b>UK's £1bn swine flu blunder left 20m vaccines unused</b>	95
3.8	A summary of the risks and benefits of vaccination	99
4	QUESTION 4: What are the risks and benefits of the homoeoprophylaxis option?	101
4.1	A history and explanation of homoeoprophylaxis.	102
4.1.1	A brief history of homoeopathy	102
4.1.2	Historical references to homoeoprophylaxis	105
4.1.3	How homoeoprophylaxis works	105
4.1.4	Some relevant facts concerning homoeoprophylaxis	108
4.1.5	Questions commonly asked about homoeoprophylaxis	111
4.2	An outline of available research into homoeoprophylaxis.	114
4.2.1	A specific homoeopathic preventative program	117
4.2.2	The general effectiveness of homoeoprophylaxis.	124
4.2.3	The Cuban Experience	133

Vaccination & Homoeoprophylaxis? A Review of Risks and Alternatives - 7 Ed

4.2.4	HP Effectiveness v's Randomised Clinical Trials and Meta Analyses	147
4.2.5	The general safety of homoeoprophylaxis	148
4.3	A comparison of different HP programs	166
4.4	The use of HP by Australian homoeopaths	168
4.5	Suggested homoeopathic prophylactics for overseas travel	171
4.6	A response to the homoeopathic sceptics	174
4.6.1	Criticisms by medical homoeopaths	174
4.6.2	The Neustaedter claims	176
4.6.3	David Little's criticisms	178
4.6.4	Types of homoeopaths	181
4.6.5	Conclusions	181
4.7	Conclusions regarding the homoeopathic option	183
PART 3: CONCLUSIONS		185
5	QUESTION 5: What are the comparative risks and benefits of the disease prevention options?	186
5.1	The comparative effectiveness of vaccination and homoeoprophylaxis	186
5.2	The comparative safety of vaccination and homoeoprophylaxis	189
5.3	A general summary of comparative risks and benefits	190
5.4	The economics of immunisation options	190
6	QUESTION 6: Which option is best for my child?	192
7	CONCLUDING COMMENTS	195
8	GENERAL APPENDICES	200
8.1	Vaccination, school entry, and conscientious objections	201
8.2	Vaccine damage register	205
8.3	Examples of change in vaccine law	208
8.3.1	The Japanese Experience	208
8.4	Reported criticisms of the homoeopathic method	211
8.4.1	Introduction	211
8.4.2	NH&MRC criticism	211
8.4.3	Choice Magazine	212
8.4.4	The medical faculties of homoeopathy quotes	212
8.4.5	The Roden paper	215

Vaccination & Homoeoprophylaxis? A Review of Risks and Alternatives - 7 Ed

8.4.6	Whooping cough in the North Coast of NSW	217
8.4.7	A Current Affair	219
8.4.8	MJA review of the homoeopathic alternative	219
8.4.9	The Australian Skeptics	220
8.4.10	The Adelaide Advertiser, 2010	222
8.4.11	Conclusions	223
8.5	Special Topics	224
8.5.1	Economics of health care	224
8.5.2	Vaccination in third world countries	225
8.5.3	My experience with the health establishment	228
8.6	Parents' support groups	236
8.7	Selected list of available reference material	239
8.7.1	Books	239
8.7.2	Journals	240
8.7.3	Other resources by Dr Isaac Golden	241
9	APPENDICES TO QUESTIONS 1, 3 AND 4	244
9.1	Appendix to Question 1: The Characteristics of Each Infectious Disease	244
9.1.1	Chicken Pox (Varicella-Zoster)	244
9.1.2	Cholera	246
9.1.3	Diphtheria	247
9.1.4	Haemophilis influenzae type b (Hib)	249
9.1.5	Hepatitis A	251
9.1.6	Hepatitis B	253
9.1.7	Hepatitis C	255
9.1.8	Influenza	257
9.1.9	Japanese encephalitis	259
9.1.10	Measles	260
9.1.11	Meningococcal disease	262
9.1.12	Mumps	265
9.1.13	Pertussis (Whooping Cough)	266
9.1.14	Pneumococcal disease	268
9.1.15	Poliomyelitis	269
9.1.16	Rubella	274

9.1.17	Tetanus	275
9.1.18	Tuberculosis	278
9.1.19	Typhoid	279
9.1.20	7th Edition Additions	281
9.1.21	Dengue Fever	281
9.1.22	Human Papiloma Virus	282
9.1.23	Leptospirosis	283
9.1.24	Rotavirus	284
9.1.25	Swine Flu	285
9.2	Appendix to Question 3: The Safety and Effectiveness of Vaccines	287
9.2.1	Chicken Pox (Varicella) vaccination	287
9.2.2	Cholera vaccination	290
9.2.3	Diphtheria vaccination	290
9.2.4	Haemophilis influenzae type b (Hib) vaccination	292
9.2.5	Hepatitis A vaccination	296
9.2.6	Hepatitis B vaccination	298
9.2.7	Hepatitis C vaccination	301
9.2.8	Influenza vaccination	301
9.2.9	Japanese Encephalitis vaccination	304
9.2.10	Measles vaccination	305
9.2.11	Meningococcal Disease vaccination	310
9.2.12	Mumps vaccination	312
9.2.13	Pertussis (Whooping Cough) vaccination	314
9.2.14	Pneumococcal Disease vaccination	328
9.2.15	Poliomyelitis vaccination	330
9.2.16	Rubella vaccination	339
9.2.17	Tetanus vaccination	341
9.2.18	Tuberculosis vaccination	344
9.2.19	Typhoid vaccination	345
9.2.20	Measles, Mumps, Rubella vaccination	346
9.2.21	Smallpox vaccination	352
9.2.22	7th Edition Additions	355
9.2.23	Dengue Fever Vaccination	355

Vaccination & Homoeoprophylaxis? A Review of Risks and Alternatives - 7 Ed

9.2.24	Human Papiloma Virus vaccination	355
9.2.25	Leptospirosis vaccination	358
9.2.26	Rotavirus vaccination	359
9.2.27	Swine Flu vaccination	361
9.3	Additional Data Supporting Homoeoprophylaxis	365
9.3.1	Historical use of Homoeoprophylaxis	365
9.3.2	The earlier homoeoprophylaxis programs, 1986, 1991, and 1993	371
9.3.3	The 1993 long-term HP program	373
9.3.4	The Original 1986 program	375
10	A Word About God	377
11	REFERENCES AND BIBLIOGRAPHY	380
	Bracho G, Varela E, Fernandez R, Ordaz B, Marzoa N, Menendez J, Garcia L, Gilling E, Leyva R, Rufin R, de la Torre R, Solis R, Batista N, Borrero R, Campa C. (2010).	382
	Massive Application of Highly Diluted Bacteria as Homeoprophylactic Formulation for Leptospirosis Epidemic Control. <i>Homeopathy</i> . 99, 156-166.	382
12	Index	409
	About the Author	411

## Index of Tables

Table 1-1	Infectious Diseases with Summary of Characteristics - 1.....	8
Table 1-2	Deaths from Measles Before and After Vaccination in 1970 ..	15
Table 1-3	Diseases Listed According to Suggested Need for Prevention for an Average, Healthy Australian Child.....	17
Table 2-1	Effects of Vitamin and Mineral Deficiencies on the Immune System.....	21
Table 2-2	Foods and Herbs Important in Supporting the Immune System .....	22
Table 3-1	A Summary of Conclusions Concerning Vaccination.....	36
Table 3-2	The Use of Mass Vaccination in Australia.....	37
Table 3-3	Standard Australian Vaccination Schedule.....	41
Table 3-4	The Variability of Clinical Trials of Vaccine Efficacy.....	55

Table 3-5 Wilson's Summary of Direct Adverse Reactions to Vaccination	58
Table 3-6 Coulter & Fisher's Short-Term Side Effects of the DPT Vaccine	60
Table 3-7 Coulter & Fisher's Long-Term Side Effects of the DPT Vaccine	61
Table 3-8 Summary of the Institute of Medicine's Conclusions by Adverse Event for DPT and RA 27/3 Rubella Vaccine	62
Table 3-9 Adverse Events Following Vaccination	64
Table 3-10 A Summary of Some of the Long-Term Side-Effects of Vaccination	67
Table 3-11 Summary of Direct Causes of Vaccine Damage	69
Table 3-12 Summary of Procedural Causes of Vaccine Damage	71
Table 3-13 Long-term Health Effects of Vaccination	73
Table 3-14 Conditions Responding to Treatment for Vaccine Damage	75
Table 3-15: Summary of Results 2001,2008	77
<b>Table 3-16 A Simple Explanation of Basic Statistical Measures</b>	<b>80</b>
Table 3-17 Reporting Rates of Adverse Events Following Immunisation (AEFI) Per 100,000 Vaccine Doses,* Children Aged Less Than Seven Years, ADRAC Database, January to June 2004	88
Table 3-18 Reporting rates of adverse events following immunisation (AEFI) per 100,000 vaccine doses,* children aged less than 7 years, ADRS database, 2007	89
Table 4-1 Some Measures of the Effectiveness of Homoeoprophylaxis	115
Table 4-2 Chronological Development of Isaac Golden's Research	116
Table 4-3 The 2004 Long-Term Homoeoprophylaxis Program	119
Table 4-4 Status Sheet for the 2004 Program	121
Table 4-5 The Current Supplementary Program	122
<b>Table 4-6 Responses Received - 15 Year Clinical Study -1988 to 2002/3</b>	<b>124</b>
Table 4-7 Summary of Results - Long-Term Homoeoprophylaxis	126
Table 4-8 Tests to Validate the Results Reporting the Efficacy of Long-Term HP	129
Table 4-9 National Attack Rates and the Efficacy of HP	131
Table 4-10 Hurricanes in Cuba in 2008	138

Table 4-11 The numbers of people immunised according to Province (to 9/4/2010).....	143
Table 4-12 Reactions to Remedies in Golden's Long-Term HP Program .....	150
Table 4-13 A Summary of the Intensity and Duration of Reactions to the Series 11-15 HP Program, by Respondent.....	153
Table 4-14 Time Profile of Definite Reactions to Program Medicines by Respondent.....	154
Table 4-15 General Comments by Users of the HP Program.....	156
Table 4-16 Definition of Degrees of Safety.....	158
Table 4-17 Ratio Analysis of the Safety of the HP-Only Immunisation Option.....	160
Table 4-18 The Relative Safety of HP - All Conditions.....	162
Table 4-19 The Relative Safety of HP - All Conditions - GP Diagnoses Only.....	164
Table 4-20 Summary of Evidence of the Safety of Long-Term HP.....	165
Table 4-21 Comparison of HP Programs.....	167
Table 4-22 Comparative results of HP Programs: Golden and Not-Golden .....	168
Table 4-23 Homoeoprophylaxis for Overseas Travel.....	172
Table 5-0-1 Comparative Safety of Vaccination and Homoeoprophylaxis .....	189
Table 6-1 A Comparison of the Options.....	193
Table 8-1: NVICS Compensation Payments 1988 to March 2008.....	207
Table 8-2 Comparison of Deaths and Notifications.....	209
Table 9-1 Studies on the Effect of Daily Administration of (I. V.) 1000mg of Ascorbic Acid as Supplement to Conventional Treatment on the Recovery of Tetanus Patients.....	277
Table 9-2 A Comparison of Measles Data.....	308
Table 9-3 The Efficacy of Whooping Cough Vaccination.....	317
Table 9-4 Comparison of Deaths and Notifications.....	321
Table 9-5 Adverse Events Occurring Within 48 Hours of DPT Vaccinations.....	322
Table 9-6 Basic Program for Protection from Birth (1993).....	373
Table 9-7 Supplementary Program for Protection When Exposed to Infection.....	374

Table 9-8 Remedies used in the 1993 program.....	375
Table 9-9 The 1986 Main Program.....	375
Table 9-10 The 1986 Supplementary Program.....	376
Table 9-11 Remedies Used in the 1986 Program.....	376

## Index of Figures

<b>Figure 3-1 Whooping Cough: USA.....</b>	<b>43</b>
Figure 3-2 Whooping Cough: England & Wales.....	44
Figure 3-3 Whooping Cough: England & Wales 1965-1985 (Detail)....	45
Figure 3-4 Whooping Cough: Australia.....	45
Figure 3-5 Measles: USA.....	46
Figure 3-6 Measles: England & Wales.....	47
Figure 3-7 Measles: Australia.....	47
Figure 3-8 Polio: USA.....	48
Figure 3-9 Polio: England & Wales.....	49
Figure 3-10 Polio: Australia.....	49
Figure 3-11 Tetanus: USA.....	50
Figure 3-12 Tetanus: England & Wales.....	51
Figure 3-13 Tetanus: Australia.....	51
Figure 3-14 Diphtheria: USA.....	52
Figure 3-15 Diphtheria: Australia.....	53
Figure 3-16: Symptom profile of the DPT vaccine.....	78
Figure 3-17: Symptom profile of the MMR vaccine.....	78
Figure 3-18 Computer Printout of Three-Week Record.....	83
Figure 3-19 Computer Printouts Summarising Breathing Patterns Over Two Months.....	84
Figure 4-1 Leptospirosis, IR and RC, 2003-2006 weekly average weighted per head of population.....	135
Figure 4-2 Leptospirosis in IR and RC, 2007, weekly, weighted per head of population.....	136
Figure 4-3 Leptospirosis in IR and RC, 2008, weekly, weighted per head of population.....	136
Figure 4-4 Leptospirosis in 2007, actual and predicted incidence.....	137
Figure 4-5 Leptospirosis cases (x10) and monthly rainfall in IR 2004-2008 with December predictive cases (x10).....	138

Vaccination & Homceoprophylaxis? A Review of Risks and Alternatives - 7<sup>th</sup> Ed

Figure 4-6	Leptospirosis cases in IR and RC from 2004 to 2008	139
Figure 4-7	The First Relationships	144
Figure 4-8	Full Cooperation	145
7-1	BMJ Effectiveness of Clinical Interventions	196
Figure 8-1	A School-Entry Vaccination Certificate	203
Figure 8-2	Conscientious Objection Form	204
Figure 8-3	Whooping Cough in Japan 1965-1991: Notifications and Deaths and Ratio of Notifications to Deaths	210
Figure 8-4	Item [a] - Letter from the Pharmaceutical Adviser to the New South Wales Health Department	231
Figure 8-5	Reply to the Pharmaceutical Adviser to the New South Wales Health Department	232
Figure 8-6	Letter from the Therapeutic Goods Administration	233
Figure 8-7	Response to Professor Dwyer article in the <i>Australian Doctor</i>	235